IDH2 and acute myeloid leukemia: Enasidenib (Idhifa), which targets IDH2, was granted approval by the US Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation as detected by an FDA-approved test (Celgene Corporation, 2017).